Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IMMP
Strong SellImmutep Limited · Healthcare · Australia · $56M · Avg Vol: $57K/d
8
StockRankGet insider-trade alerts
Q
29
V
34
M
16
P/E (TTM)
—
ROE
-61.8%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.1M | 0 | 0 | — | — | — | 12.3M | 2.3M | 79.3% |
| EPS | -1.64 | -2.60 | -2.51 | -0.30 | — | -0.36 | -0.23 | -0.14 | — |
| Shares | 147.4M | 147.4M | 147.4M | — | 0.0% | 147.4M | — | — | — |
| Debt | 1.2M | 0.9M | 1.1M | — | -4.1% | 0.9M | — | — | — |
| Equity | 67.4M | 97.8M | 135.8M | — | 41.9% | — | — | — | — |
| Op CF | -31.5M | -25.3M | -24.9M | — | — | -44.6M | — | — | — |
| Inv CF | -16.4K | -59.3K | -15.1M | — | — | — | — | — | — |
| Fin CF | 36.1M | 54.5M | 68.2M | — | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-7.1%
SMA 50SMA 200
Close
$0.381
RSI (14)
50.5
52W High
$3.53
From 52W High
0.1%
SCORE BREAKDOWN
Quality
29
ROIC (ROA)
-32.1%*24.5
ROE
-61.8%16.2
GP/Assets
-38.6%2.3
Op. Margin
-763.7%8.4
FCF/Assets
-17.7%23.9
Piotroski
560.6
Int. Cover
—N/A
D/E Ratio
0.01x83.3
Current Ratio
2.97x53.7
Value
34
P/E (TTM)
—N/A
EV/EBITDA
0.7x25.0
P/FCF
—N/A
P/B
1.1x81.5
P/S
9.8x27.5
Div Yield
—N/A
Momentum
16
52W High %
11%1.1
RS 6M
-99%0.2
SMA 50/200
0.30x0.5
EPS Rev 4W
0.0%34.6
EPS Rev 12W
—N/A
EPS Improve
+44%52.5
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$56M
P/E (Forward)
-1.9x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IMMP are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IMMP | Immutep Limited(you) | $56M | 8 | Strong Sell |
| BOT.AX | Botanix Pharmaceuticals Limited | $51M | 9 | Strong Sell |
| ALA.AX | Arovella Therapeutics Limited | $53M | 14 | Strong Sell |
| RCE.AX | Recce Pharmaceuticals Ltd | $81M | 2 | Strong Sell |
| PAR.AX | Paradigm Biopharmaceuticals Limited | $91M | 4 | Strong Sell |
| DXB.AX | Dimerix Limited | $118M | 9 | Strong Sell |
| PTX.AX | Prescient Therapeutics Limited | $50M | 22 | Sell |
| LTP.AX | LTR Pharma Limited | $61M | 24 | Sell |
| ILA.AX | Island Pharmaceuticals Limited | $93M | 19 | Strong Sell |
| ATX.AX | Amplia Therapeutics Limited | $53M | 30 | Sell |
Peer medians: ROE -19.4% · P/E 34.6x · Gross margin 62.6%